Understanding genetic factors in Alzheimer's and related neurodegenerative diseases
Core C: Genomics and Transcriptomics
This study is looking at the genes of people with Alzheimer's and ALS to see how certain genetic changes might affect the way these diseases progress, and it aims to create a score that helps understand each person's risk based on their genetics, which could lead to better treatments in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10891473 on NIH RePORTER |
What this research studies
This research focuses on analyzing genetic information from patients with neurodegenerative diseases, particularly Alzheimer's and Amyotrophic Lateral Sclerosis (ALS). By utilizing existing whole genome sequencing data from 721 individuals, the project aims to identify variations in genes related to tau metabolism, which is crucial for understanding disease progression. The research will also develop a tau polygenic risk score to categorize patients based on their genetic risk for tau-related neurodegeneration. This information will help in understanding how genetic factors influence disease mechanisms and could guide future treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, ALS, or other related neurodegenerative conditions.
Not a fit: Patients with non-neurodegenerative conditions or those without a genetic predisposition to tau-related diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and potential new treatments for Alzheimer's and related neurodegenerative diseases.
How similar studies have performed: Previous research has shown promise in using genetic analysis to understand neurodegenerative diseases, making this approach both relevant and potentially impactful.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Yokoyama, Jennifer S — University of California, San Francisco
- Study coordinator: Yokoyama, Jennifer S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.